Tarsus Pharmaceuticals (TARS) Non-Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $43.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 119.78% year-over-year to $43.9 million in Q1 2026; TTM through Mar 2026 was $136.7 million, a 85.48% increase from a year earlier, with the FY2025 full-year figure at $39.4 million, up 94.1% from the prior year.
• Non-Current Assets advanced to $43.9 million in Q1 2026 per TARS's latest filing, from $39.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $43.9 million in Q1 2026 and bottomed at $2.4 million in Q3 2022.
• The 5-year median for Non-Current Assets is $9.4 million (2023), against an average of $15.0 million.
• Across the five-year window, Non-Current Assets dropped 28.19% in 2022 and jumped 279.35% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $2.5 million in 2022, then jumped by 276.21% to $9.4 million in 2023, then surged by 116.73% to $20.3 million in 2024, then jumped by 94.1% to $39.4 million in 2025, then rose by 11.5% to $43.9 million in 2026.
• Per Business Quant, the three latest TARS Non-Current Assets figures stand at $43.9 million (Q1 2026), $39.4 million (Q4 2025), and $32.9 million (Q3 2025).